当前位置: X-MOL首页最新SCI期刊查询及投稿分析系统 › Therapeutic Advances in Medical Oncology杂志
Therapeutic Advances in Medical Oncology
基本信息
期刊名称 Therapeutic Advances in Medical Oncology
THER ADV MED ONCOL
期刊ISSN 1758-8340
期刊官方网站 http://tam.sagepub.com/
是否OA
出版商 SAGE Publications Inc.
出版周期
始发年份
年文章数 67
最新影响因子 4.9(2022)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 ONCOLOGY 肿瘤学2区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 5.44 2.200 1.659
Medicine
Oncology
33 / 321 89%
补充信息
自引率 1.20%
H-index 24
SCI收录状况 Science Citation Index Expanded
官方审稿时间
网友分享审稿时间 数据统计中,敬请期待。
PubMed Central (PML) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1758-8340%5BISSN%5D
投稿指南
期刊投稿网址 https://us.sagepub.com/en-us/nam/journal/therapeutic-advances-medical-oncology#submission-guidelines
收稿范围

Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The editors welcome original research articles across all areas of oncology.

The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.


收录体裁
投稿指南
投稿模板
参考文献格式
编辑信息

Managing Editor

Georgia Patey       SAGE Publications Ltd, UK

Associate Editors

Ian Davis Eastern Health Clinical School, Monash University, Australia

Axel Grothey  Mayo Clinic, Rochester, MN, USA

Nadia Harbeck      University of Munich, Germany

Sara Hurvitz   University of California, Los Angeles, CA, USA

Jonathan Ledermann   UCL Cancer Institute, London, UK

Karl Lewis      University of Colorado Denver, Denver, CO, USA

Keunchil Park Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

Antonio Rossi IRCCS Casa Sollievo della Sofferenza, Italy

Takayuki Yoshino  National Cancer Center Hospital East, Chiba, Japan

Editorial Board

Dirk Arnold    Instituto CUF de Oncologia, Lisbon, Portugal

Carlos L Arteaga   Vanderbilt University, Nashville, TN, USA

Tanya B. Dorff       City of Hope, Duarte, CA, USA

Christopher Benz  Buck Institute for Research on Aging, UCSF, Novato, CA, USA

Michael Boyer       University of Sydney, Sydney, Australia

Kim N Chi      University of British Columbia, Vancouver, BC, Canada

Toni K Choueiri     Dana-Farber Cancer Institute, Boston, MA, USA

Ronald de Wit       Erasmus University Medical Center, Rotterdam, The Netherlands

Wilfried Eberhardt University Duisburg-Essen, Essen, Germany

Tim Eisen       Cambridge University, Cambridge, UK

Alfredo Falcone    University of Pisa, Pisa, Italy

Michael Findlay     University of Auckland, Auckland, New Zealand

Jorge A. Garcia     Cleveland Clinic, Cleveland, OH, USA

Cesare Gridelli      S.G. Moscati Hospital, Avellino, Italy

Nasser H. Hanna   Indiana University School of Medicine, Indianapolis, IN, USA

Paul R Helft   Indiana University School of Medicine, Indianapolis, IN, USA

Maha Hussain      Northwestern University Lurie Cancer Center, Chicago, IL, USA

David H Ilson Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Sung-Bae Kim      University of Ulsan, Seoul, South Korea

Ragini Kudchadkar       Emory University School of Medicine, Atlanta, GA, USA

James Larkin  Royal Marsden Hospital, London, UK

Robert R McWilliams    Mayo Clinic, Rochester, MN, USA

Sofia Merajver      University of Michigan, Ann Arbour, MI, USA

Mark Middleton    Oxford University, Oxford, UK

Paul Nathan  Mount Vernon Cancer Centre, Northwood, UK

Sylvie Negrier Centre Léon-Bérard, Lyon, France

Harvey I Pass New York University Medical Center, New York, NY, USA

Edith A Perez Mayo Clinic, Jacksonville, FL, USA

Robert Pirker Medical University of Vienna, Vienna, Austria

Emilio Porfiri  Queen Elizabeth Hospital Birmingham, Birmingham, UK

David Quinn  University of Southern California, Los Angeles, CA, USA

Bhupendra Rawal  Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, MA, USA

Joseph D Rosenblatt    University of Miami, Miami, FL, USA

Frances Shepherd Princess Margaret Hospital, Toronto, ON, Canada

Josep Tabernero   Vall d'Hebron University Hospital, Barcelona, Spain

Scott Tagawa Weill Cornell Medicine, New York, NY, USA

Bruno Vincenzi     University Campus Bio-Medico, Rome, Italy

Toni Wozniak Wayne State University, Detroit, MI, USA

Andrew X Zhu       Massachusetts General Hospital Cancer Center, Boston, MA, USA


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug